Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.
复制标题
DOI：
10.3389/fmicb.2016.02173
复制
发表时间：
2016
影响因子：
5.2
通讯作者：
Rogers PD
中科院分区：
文献类型：
--
作者：
Whaley SG;Berkow EL;Rybak JM;Nishimoto AT;Barker KS;Rogers PD
在有限的抗真菌药物中，唑类抗真菌药物是最常用于治疗念珠菌感染的一类药物。唑类抗真菌药物，如氟康唑，通常是治疗许多念珠菌感染的首选药物，因为它们价格便宜，毒性有限，而且可以口服。然而，有大量文献记载了几种念珠菌对唑类抗真菌药物固有的和发展的耐药性。随着临床上耐唑类念珠菌的增多，阐明其耐药机制是必要的，以便保存和改进用于治疗念珠菌感染的唑类抗真菌药物。本文综述了白色念珠菌、热带念珠菌、克鲁斯假丝酵母菌、光滑念珠菌等非白色念珠菌感染中的唑类耐药情况，特别介绍了这些真菌对唑类耐药性的分子基础的研究现状。
Within the limited antifungal armamentarium, the azole antifungals are the most frequent class used to treat Candida infections. Azole antifungals such as fluconazole are often preferred treatment for many Candida infections as they are inexpensive, exhibit limited toxicity, and are available for oral administration. There is, however, extensive documentation of intrinsic and developed resistance to azole antifungals among several Candida species. As the frequency of azole resistant Candida isolates in the clinical setting increases, it is essential to elucidate the mechanisms of such resistance in order to both preserve and improve upon the azole class of antifungals for the treatment of Candida infections. This review examines azole resistance in infections caused by C. albicans as well as the emerging non-albicans Candida species C. parapsilosis, C. tropicalis, C. krusei, and C. glabrata and in particular, describes the current understanding of molecular basis of azole resistance in these fungal species.